A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy

NCT01493453 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Investigation into serious breach

Conditions

CD19 Positive Non-Hodgkin Lymphoma

Interventions

GENETIC: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine

Sponsor

The Christie NHS Foundation Trust